First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Search
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
How Simulation is Changing the Game in Biotherapeutic Drug Development
How Simulation is Changing the Game in Biotherapeutic Drug Development
BI Starts Clinical Study on Interchangeability | Boehringer Ingelheim US
BI announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study, for an adalimumab biosimilar candidate.
A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US
A Moment To Reflect on the Evolving Approach for Diabetes Management
An Employee’s Commitment to Ensuring Access to Medicines
An Employee’s Commitment to Ensuring Access to Medicines
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Biosimilar Candidate to Humira® Accepted For Review | BI US
Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.
Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals
Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals
Data Privacy App
Data Privacy App
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise
Focus on Alliance Management
Focus on Alliance Management
Standing together in support of improved access to obesity care
Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".
Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner
Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner
Fighting Rabies in Madagascar | Boehringer Ingelheim US
Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics
FDA Grants BTD for Investigational Treatment of CIAS | BI US
Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach